Finding Value in ETF's Worth Owning for the Long Haul
Is the Health Sector a good place to invest?
The Health Care Select Sector SPDR® Fund (XLV) is the oldest and largest Health Sector ETF available. Its’ inception date was on December 16, 1998.
XLV vs S&P 500 index fund: January 1999 – August 2019
Source: https://www.portfoliovisualizer.com/
XLV vs SPY: December 22, 1998 – September 6, 2019
Source: https://www.koyfin.com/home Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.3”
Health Care Select Sector SPDR® Fund (XLV) vs S&P 500 index fund: January 1999 – September 2018
Source: https://www.portfoliovisualizer.com/
Continue reading “Best Long-Term Performance Health Sector ETFs 1.2”
The biotech ETF is up more than 20% this year, earning a spot on IBD’s ETF Leaders screen. It’s done that with a portfolio that’s concentrated on just 30 holdings.
— Read on www.investors.com/etfs-and-funds/etf-leaders/biotech-etf-first-trust-nyse-biotechnology-index-fund/
“Biotechnology has been on the cutting edge of healthcare for years, and countless new treatments have made life better for millions of people across the globe. Investing in biotechnology companies can be extremely risky, because the success or failure of a single candidate treatment can make or break the company’s entire future.”
Continue reading at Yahoo Finance: The 4 Top Biotech ETFs
We trimmed some more profits off of our biotech holdings today. (FBT) First Trust NYSE Arca Biotechnology Index Fund. Price paid $92.38. Price sold $145.38. Read why we invest in FBT right here: Discovering Value in Growth Stock Funds: Biotech ETFs
Biotechs are zooming again. We trimmed some more fat from our biotech holdings today. I still believe the First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is a great investment. You can read why we invest in FBT right here: Discovering Value in Growth Stock Funds: Biotech ETFs. Price paid $92.38. Price sold $129.68.
We trimmed some fat off our Biotech holdings today. First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great ETF; we’re just taking some profits off the table. Price paid $91.61. Price sold $127.58.
Here’s what I wrote about the Biotech sector in January 2017: Discovering Value in Growth Stock Funds: Biotech ETFs
We sold some of our Biotech holdings today. I don’t currently see any problems in this is industry or this particular ETF at this time. We only sold to use the funds in another endeavor. Price paid $89.36, price sold $117.12. The First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great fund and I still recommend it to other investors. I wrote about FBT back in January 2017 and updated the charts in the article in May 2017 right here: Discovering Value in Growth Stock Funds: Biotech ETFs
We sold some of our Biotech equities today. (FBT : $FBT) No problem with the First Trust NYSE Arca Biotechnology Index Fund (FBT); just taking some profits off the table. Price paid $91.89. Price sold $119.87.
Here’s an article I wrote about FBT back in January 2017: Discovering Value in Growth Stock Funds: Biotech ETFs
Are Biotech Funds Buys Once Again?
While a number of market industries were fearful of a Trump Presidency, nowhere was the concern more prevalent than in the biotech and drug segment. After all, Trump came out several times against the pricing practices in the drug market, vowing to do something to make this a more affordable area…. (Read full article at Zacks.)
Continue reading “Discovering Value in Growth Stock Funds: Biotech ETFs 1.1”
